Directed Activation of T Cells for Cytotoxicity Assays

T cells are critical to the adaptive immune system as they recognize and destroy pathogenic cells while leaving healthy cells unharmed. As such, they are a promising focus for novel cancer therapies. Key processes in these T cell immunotherapies are the directed activation and expansion of a patient’s own T cells in vitro. The activation proceeds through the addition of antigens, and often, IL- 2. To strengthen the response by directing the activation, and better mimicking in vivo behaviors, the T cells may be cultured in the presence of target cells. This method directs T cell activation towards target cell antigens.

The activation process occurs over multiple days in microplates and is amenable to automation. Liquid handlers like the Agilent BioTek MultiFlo FX multimode dispenser can be used to seed both target and T cells. The Agilent BioTek AMX automated media exchange module is deployed to automatically perform media exchanges over the course of the activation without loss of the nonadherent T cells. The Agilent BioTek Cytation cell imaging multimode reader, in conjunction with Agilent BioTek BioSpa 8 automated incubator can be used to periodically image both target and T cells during the activation process.

 

Directed T cell activation in a microplate well imaged in brightfield using Cytation.
Figure 1. Directed T cell activation in a microplate well imaged in brightfield using Cytation.

Application Notes

 

>> BACK TO IMMUNO-ONCOLOGY

GET MORE INFO

 

For Research Use Only. Not for use in diagnostic procedures.

RA44218.4093171296

 

link